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Background. Strictures are a common complication in Crohn’s disease (CD), found in more than 50% of patients. *ey are
characterized by the excessive deposition of extracellular proteins in the tissue as a result of the chronic inflammatory process.*e
effect of anti-tumor necrosis factor alpha (TNF-α) therapy on the development of fibrosis is not yet fully understood. Aim. To
investigate whether the degree of intestinal inflammation and fibrosis is correlated with preoperative anti-TNF-α therapy in
patients with CD who are undergoing bowel resection. Methods. *is unblinded, prospective, single tertiary center, pilot cohort
study included all adult patients with CD who underwent elective, laparoscopic, or open intestinal resection. Preoperative
investigations included measurement of blood TNF-α concentration, specific antidrug antibodies, and the concentration of
selected inflammatory cytokines. *ree pathologists independently examined the specimens and assessed the degree of in-
flammation and fibrosis. Results. Histopathological specimens from 10 patients with CD who underwent ileocecal or ileocolic
resections were retrieved. Four of those patients were on anti-TNF-α treatment prior to surgery. *e last dose of the anti-TNF-α
agent was administered 1–9 weeks prior to bowel resection. Patients on anti-TNF-α treatment had a higher fibrosis score than
controls (p � 0.01). Anti-TNF-α treatment was not associated with an increase in CD68- or CD163-positive macrophages. *ere
was no significant relationship between the time from the final preoperative anti-TNF-α dose to surgery and the fibrosis score. No
significant association was found between the concentration of major inflammatory cytokines, including TNF-α, and the fibrosis
score or degree of inflammation. Conclusions. Patients who underwent preoperative anti-TNF-α treatment had a higher fibrosis
score than controls.
1. Introduction
More than 50% of patients with Crohn’s disease (CD) will
develop intestinal fibrosis (stenosis and strictures) as a result
of chronic inflammation [1].
Persistent and recurring tissue injury from inflamma-
tion, which is triggered and sustained by proinflammatory
cytokines, leads to a continuous cycle of tissue breakdown
and repair. *is results in the accumulation of fibroblasts
and myofibroblasts, which may lead to fibrosis as a result of
extracellular matrix production [2].
Clinically, strictures may occur as a result of inflam-
mation-mediated swelling of the intestinal wall, fibrotic
occlusions, or a combination of both [3]. It is well known that
immunosuppressive drugs, including TNF-α inhibitors, may
reduce the occurrence of inflammatory strictures; however,
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their effect on the fibrotic reaction is not clear [4]. As chronic
inflammation is closely associated with fibrosis and stricture
formation, and considering the key role of TNF-α in initi-
ating the inflammatory response [5], we hypothesized that
anti-TNF-α therapy may lead to reduced fibrosis.
Intestinal macrophages have many important functions
in maintaining gut homeostasis, but they also play a role in
the development of inflammation. When identifying mac-
rophages in tissue by immunohistochemistry, two widely
used macrophage markers are CD68 and CD163 [6].
*e aim of the present study was to investigate whether the
degree of intestinal fibrosis, inflammation, and the number of
macrophages are correlated with preoperative anti-TNF-α
therapy in patients with CD undergoing bowel resection.
2. Materials and Methods
2.1. Study Design. *is is an unblinded, prospective, non-
interventional, pilot cohort study.
2.2. Study Hypothesis. Patients with CD who receive pre-
operative treatment with anti-TNF-α drugs will have less
inflammation and a lower degree of intestinal fibrosis,
assessed by CD163 concentration in the peripheral blood
and histology, when compared to anti-TNF-α näıve patients.
2.3. OutcomeMeasures. *e primary outcome measure was
the degree of fibrosis. *e secondary outcome was the grade
of inflammation.
2.4. Inclusion Criteria. All adult patients with CD who were
scheduled for elective small bowel or colon resection (open
or laparoscopic) from a single tertiary center were included.
2.5. Exclusion Criteria. All patients with sepsis (abscess or
fistula) or acute intestinal obstruction were excluded.
2.6. Extracted Data. *is study is a continuation of the
Inflammatory Bowel Disease Response study [7], in which
resection specimens were obtained from patients under-
going elective ileocecal or ileocolic resections. Surgery and
acquisition of the resection specimens were carried out as
described previously [7].
Patient demographics, disease severity, nutritional sta-
tus, comorbidities, preoperative medications, previous op-
erations for CD, presence of preoperative intra-abdominal
abscess or enteric fistula, preoperative nutritional support,
disease duration, and disease localization were registered
after obtaining oral and written informed consent. Blood
samples were collected preoperatively and at 6, 24, and 48
hours after the surgical incision. Laboratory workup in-
cluded serum analyses for TNF-α, interleukin- (IL-) 6, IL-8,
IL-10, and IL-17A, in addition to white blood cell count,
total iron-binding capacity, and C-reactive protein, albumin,
hemoglobin, D-dimer, and cortisol levels. *e drug con-
centration in the serum was measured in addition to the
antidrug antibodies titer.
Out of the 46 patients included in the IBD Response
study, bowel specimens from 10 patients with CD met the
inclusion criteria and were eligible for analysis. Four of the
10 included patients had received TNF-α treatment pre-
operatively, with the last dose administered 1–9 weeks prior
to surgical intervention. Representative hematoxylin and
eosin (H&E)-stained slides from each of the resection
specimens were chosen for further analysis. Fibrosis was
assessed by Masson trichrome (MT) staining. Examples of
fibrosis stained blue in Masson Trichrome special stain are
shown in Figure 1.
To assess the number of macrophages, the immunohis-
tochemical markers CD68 and CD163 were used. *e slides
were digitalized using a Hamamatsu slide scanner™ and
image processing was subsequently performed in Vis-
iopharm™. For both markers, deparaffinized sections were
stained in a Ventana BenchMark ULTRA XT automatic
stainer using 3,3′-diaminobenzidine (DAB) (OptiView
universal DAB IHC detection kit; Ventana BioTek System,
Tucson, AZ, USA), performed according to the manufac-
turer’s instructions. Briefly, sections were demasked with cell
conditioning buffer (CC1, VentanaMedical Systems, Tucson,
AZ, USA) for 8min followed by 16min, and endogenous
peroxidase activity was blocked with the UltraView inhibitor.
Primary antibodies against CD68 (PREP KIT 54) and CD163
(CD163 [MRQ-26]) were applied for 32min at 36°C. Sections
were then incubated with OptiView horseradish peroxidase
(HRP) multimer (Ventana BioTek Systems), containing a
mixture of HRP-labeled goat anti-mouse and goat anti-rabbit
antibodies. Bound antibodies were visualized by incubation
with OptiView hydrogen peroxide substrate and DAB
chromogen, and counterstained with hematoxylin. Positive
signals for both CD68 and CD163markers were evidenced by
a brown color reaction in the cell cytoplasm.
Slides were evaluated by two consultant pathologists
(PDD and JJC) and one trainee pathologist (UK) to mini-
mize interobserver variation. *e pathologists were blinded
to the patients’ clinical data and diagnosis. *e three in-
dependent observers graded the degree of fibrosis on the
MT-stained slides on a scale of 1–4. *e grading was per-
formed semi-quantitatively by assessing the amount of blue-
stained fibers in the representative areas.
Acute and chronic inflammation was assessed in all four
layers of the intestinal wall, and graded as absent, mild,
moderate, or severe. *e inflammation grades were deter-
mined semi-quantitatively by eyeballing, with a triple head
microscope. Disagreements were resolved by consensus, and
grades were assigned a numerical value from 0–3 for statistical
analysis. *e grades were defined as follows: absent (0), no
traces of inflammation; mild (1), few inflammatory cells (mild
acute inflammation in mucosa was defined as neutrophils in
the lamina propria); moderate (2), moderate amount of in-
flammatory cells (moderate acute inflammation in mucosa
was defined as the presence of cryptitis); and severe (3), many
inflammatory cells (severe acute inflammation in mucosa was
defined as the presence of crypt abscess).
Areas of ulceration were excluded from the analysis.
*e immunohistochemical slides were assessed inde-
pendent to the HE-stained sections in a blinded manner.
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Positive immunohistochemical staining was defined as cy-
toplasmic staining for CD68 and CD163. To assess the
number of CD68- and CD163-positive cells, the areas of
mucosa, submucosa, and muscularis propria deemed to
contain the most CD163-positive cells under 4× magnifi-
cation were selected. *e CD68 and CD163 slides were then
aligned, and each observer counted the number of positive
CD68 and CD163 cells in the selected area (110,000 μm2) at
20x magnification. A representative image of CD68 staining
is presented in Figure 2.
2.7. Statistical Analysis. For the fibrosis analysis, the mean
value of each independent observers’ scores were calcu-
lated and used as the final result. Student’s t-test was
applied for all observations. *e kappa score for inter-
observer agreement was calculated using Fleiss’ kappa for
more than two raters. For the univariate analysis, Pearson’s
chi-square and Fisher’s exact tests were employed. Con-
tinuous data were compared using the Mann–Whitney U
test and one-way ANOVA. *e relationship between
continuous variables was analyzed using Pearson’s chi-
square correlation. Due to the small sample size of this
pilot study, multivariate logistic regression was not used.
SPSS version 19 software (IBM SPSS Statistics for Win-
dows, Version 22.0; Armonk, NY: IBM Corp.2010) was
used for all statistical analyses.
3. Results
3.1. Study Population Characteristics. Patients’ characteris-
tics are shown in Table 1. *e mean age was 40.10 (±12.97
SD) years. Five patients were female. None of the patients
had comorbidities.
3.2. Drug Levels at the Time of Operation. Four patients who
underwent preoperative treatment with anti-TNF-α received
their last dose 1–9 weeks prior to bowel resection. *ree of
the four patients who were on anti-TNF-α treatment had no
detectable drug concentration at the time of operation. One
patient was positive for antidrug antibodies at the time of
operation, although this patient had an undetectable drug
concentration.
3.3. Fibrosis. *e patients’ fibrosis scores are presented in
Table 2. Patients on anti-TNF-α treatment had a higher
fibrosis score compared to controls (p�0.01). *ere were no
significant relationships between the number of weeks of
administration of anti-TNF-α agents and the fibrosis score,
CD68 or CD163 levels. *e fibrosis score was not correlated
with CD68 or CD163 levels. Preoperative and 6 h postop-
erative TNF-α concentrations were not correlated with the
fibrosis score. *e disease duration was not correlated with
the degree of fibrosis.
3.4. Grade of Inflammation. Grades of acute and chronic
inflammation are presented in Table 2. Patients on anti-
TNF-α treatment showed no difference in inflammation
compared to the controls. Neither the duration of anti-TNF-
α treatment nor the anti-TNF-α drug concentration was
associated with the grade of inflammation.
3.5.MacrophageMarkers CD68 andCD163. *e presence of
CD68 and CD163 in the submucosa of patients with CD
were significantly correlated (p � 0.014), but not in the
mucosa or muscularis propria. *e concentrations of in-
flammatory markers (TNF-α, IL-6, IL-8, IL-10, IL-17, and
cortisol) showed no significant correlations with CD68 or
CD163, whether in the mucosa, submucosa or muscularis
propria. Anti-TNF-α treatment was not associated with an
increase in CD68 or CD163. No significant correlations were
observed between preoperative C-reactive protein levels and
fibrosis score, CD68 or CD163.
4. Discussion
*ere was no significant relationship between the duration
of anti-TNF-α administration and the fibrosis score. *is
might be explained by differences in disease duration, the
development of fibrosis prior to medication, or genotypic
and phenotypic differences between patients. An allele that
could lead to overexpression of the main profibrotic
mediator, TGF-β, has been identified [8], which could lead
to more rapid development of fibrosis and strictures.
Another explanation could be that inflammation and fi-
brosis are initially linked in the pathogenesis, but later
become two independent processes [9]. *is might explain
why fibrosis cannot be reversed by anti-inflammatory
drugs.
*e duration of anti-TNF-α treatment was not signifi-
cantly correlated to either of the macrophage-associated
receptors (CD68 and CD163). CD163 serves as a marker for
activated macrophages in its soluble form [10]. Although the
CD163 marker has been linked to the anti-inflammatory M2
macrophage phenotype, CD163-positive macrophages have
been found to outnumber CD68-positive cells in a range of
inflammatory events, including those that are associated
with CD [6]. Dige et al. found that administration of anti-
TNF-α led to a significant reduction in soluble CD163 when
compared to biologic-naı̈ve controls [10]. In the present
study, we did not find such a correlation. *is may be as-
cribed to the fact that plasma concentrations, rather than
500µm 
Figure 1: Example of fibrosis stained blue in Masson Trichrome
special stain.
Surgery Research and Practice 3
tissue concentrations, were measured in the Dige et al. study
[10]. In addition, none of the patients had detectable drug
levels at the time of operation, which might also explain why
CD163 concentrations were not attenuated.
In order to measure the number of macrophages, two
cellular markers, CD68 and CD163, were chosen. CD68 is a
pan-macrophage marker [11], whereas CD163 is a macro-
phage-specific scavenger receptor with anti-inflammatory
abilities in M2 macrophages. When macrophages are acti-
vated, CD163 proteins are shed into the bloodstream [10]. By
measuring soluble CD163, one can monitor the number of
activated macrophages in the host. Consequently, elevated
levels of CD163 are associated with conditions with a
heightened inflammatory response, such as CD [10]. Using
this method, however, no correlation between fibrosis and
the number of macrophages was found. Additionally, no
correlations were found between various cytokines (TNF-α,
IL6 IL8, IL10, and IL17) and cortisol and CD68 and CD163.
If this holds true in a larger population, it could indicate that
macrophages play amore active role in inflammation than in
the development of fibrosis. Alternatively, the question must
be raised as to the accuracy of these markers for measuring
the degree of fibrosis.
*e lack of association between treatment with the anti-
TNF-α drug and a decrease in inflammation is remarkable,
as its main effect is to inhibit the proinflammatory cytokine
TNF-α. *is could indicate that the effect of the drug is
subeffective or ineffective in the target tissue. Previous
studies have concluded that inflammatory processes may
be confined to the fibrostenotic tissue, which may be
beyond the reach of anti-TNF-α drugs [12]. Also, of the
patients in the treatment group, half had received their last
dose 9 weeks prior to surgery, which might be too long to
detect a decrease in inflammation. If this is the case, it may
explain why we observed no reductions in fibrosis or in
macrophage activity.
*e increase in fibrosis found in this study may seem
counterintuitive considering its effectiveness against in-
flammation. *is has been reported in other studies, and the
general explanation is that TNF-α counterbalances the ef-
fects of TGF-β. Inhibition of TNF-α might therefore pro-
mote the profibrotic signaling cascade [13]. Although
previous studies have found a significant decrease in in-
flammation in the treatment group, there was a significant
increase in pauci-inflammatory fibrosis in the muscularis
mucosae, as well as a trend toward increased fibrosis in the
muscularis propria, albeit not statistically significant. *is
was ascribed to the classic “lattice-like” healing pattern also
seen in endoscopy after anti-TNF-α treatment [13]. Since its
introduction, theories related to the role of anti-TNF-α in
the development of fibrosis have been subject to debate.
Although several studies conducted on large populations
have failed to produce evidence that support such a claim,
concerns regarding the drug’s potential in causing fibrosis
and strictures in these patients still remain [13].
We suspect that the increased fibrosis score observed in
patients with CD on anti-TNF-α treatment in the current
study indicates a nonresponse to the treatment because a
500µm 
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Figure 2: Example of cell cytoplasmatic staining of macrophages using the CD68 immunohistochemical marker.
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response would have limited inflammation and fibrosis. *is
hypothesis is to be investigated in a large prospective cohort
study.
5. Limitations
*is study was a pilot study that can serve as a template for
future larger-scale studies. *e two groups were not
comparable with regard to age, gender, disease duration,
preoperative events, and surgical approach. *e patients in
the control group seemed to be more sick (older, longer
disease duration, and open surgery), which would translate
to more inflammation and fibrosis. *e study population
was a group of patients in whom the medical treatment was
not sufficient to avoid operation, and nonresponders to anti-
TNF-α treatment may differ to responders with regard to the
Table 1: Preoperative and intraoperative characteristics of 10 patients with Crohn’s disease treated with anti-TNF-α compared to anti-TNF-
α naı̈ve patients.
Patients’ characteristics Anti-TNF-α treatment4/10 patients (40%)
Anti-TNF-α näıve
6/10 patients (60%) Univariate analysis
Age (years; mean± SD) 27.4± 10.25 48.5± 5.28 p � 0.003
Female 3/4 (75%) 2/6 (33.3%) Ns
Body mass index (kg/m2; mean± SD) 26.58± 11.8 22.5± 2.17 Ns
Smoking, n (%): Ns
Non- or ex-smoker 3/4 (75%) 6/6 (100%)
Smoker 1/4 (25%) 0/6 (0%)
Steroids, n (%) 0 3/6 (50%) Ns
Immunomodulators, n (%) 1/4 (25%) 2/6 (33.3%) Ns
Disease localization (Montreal classification) Ns
L2 1/4 (25%)
L3 3/4 (75%)
Harvey–Bradshaw Index>median (7.5), n (%) 1/4 (25%) 3/6 (50%) Ns
Disease duration (years; mean± SD) 5± 3.16 14.33± 9.05 Ns
Disease phenotype (Montreal classification) Ns
B2 (stricturing) 4/4 3/6 (50%)
B3 (penetrating) 0 3/6 (50%)
Previous laparotomy/laparoscopy for CD 1/4 (25%) 3/6 (50%) Ns
Preoperative parenteral nutrition, n (%) 0 1/6 (16.7%) Ns
Preoperative sepsis 0 2/6 (33.3%) Ns
Preoperative CRP mg/L (mean± SD) 32.18± 37.5 19.35± 19.28 Ns
Preoperative TNF-α ng/L (mean± SD) 1.22± 2.14 0.37± 0.35 Ns
Access to abdomen, n (%) p � 0.005
Laparoscopic 4/4 0
Open 0 6/6
Type or resection, n (%) Ns
Small bowel resection 0 2/6 (33.3%)
Ileocolic resection 4/4∗ 4/6 (66.7%)∗
All operations were performed with a specialist surgeon in charge. Anti-TNF-α, anti-tumor necrosis factor alpha drugs; Ns, nonsignificant; CRP, C-reactive
protein; SD, standard deviation. ∗In each group that underwent ileocolic resection, one patient also received colectomy.
Table 2: Drug administration, fibrosis score, and inflammation grade of patients with Crohn’s disease.
Birth year Gender (m/f ) Anti-TNF-α dose (mg) TPS (weeks)
Fibrosis
score
Acute inflammation
grade
Chronic inflammation
grade
P1 P2 P3 Mu SM MuP SS Mu SM MuP SS
1997 f 40 1 4 3 4 2 1 0 0 3 3 1 2
1993 m 100 9 3 3 3 1 0 1 0 1 2 1 1
1974 m 0 — 2 2 3 2 1 0 0 2 2 2 1
1963 m 0 — 1 1 1 3 0 1 0 1 3 2 11 1 2 1 0 0 0 1 1 1 0
1965 f 0 — 2 3 2 2 0 0 1 1 2 0 1
1962 m 0 — 2 3 4 1 0 0 1 2 3 2 22 1 2 3 0 1 0 2 3 1 2
1982 f 40 1 3 3 4 1 0 0 1 2 2 1 1
1962 f 0 — 2 3 3 3 1 1 0 2 3 2 3
1972 m 0 — 1 2 1 3 1 0 1 1 1 0 1
1975 f 100 9 4 4 4 2 0 1 2 0 13 3 4 1 0 0 0 0 0 0 1
TPS, time prior to surgery; P1–3, pathologists 1–3; Mu, mucosa; SM, submucosa; MuP, muscularis propria; SS, subserosa.
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formation of fibrosis. Logistic regression analysis to adjust
for confounders was considered, but due to the small sample
size, and after consulting a biomedical statistician, this was
deemed inappropriate.
6. Conclusion
Patients who received preoperative anti-TNF-α treatment
had a higher fibrosis score compared to controls. A sig-
nificant correlation between the duration of drug admin-
istration and fibrosis score could not be found. Furthermore,
there was no correlation between the duration of drug
administration and the number of CD68 and CD163
macrophage receptors. *e degree of acute and chronic
inflammation was not significantly different between the two
groups. *ere is a need for a large prospective study.
Data Availability
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Additional Points
Perspectives. Histopathological examination of fibrosis and
inflammation might indicate whether the patient will re-
spond to biological treatment.
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